HEXIM1 Human
Description
Product Specs
Product Science Overview
HEXIM1 was initially identified as a gene induced by hexamethylene bis-acetamide (HMBA), a compound known to induce differentiation in certain cell types . The protein encoded by this gene is involved in the regulation of RNA polymerase II (RNAPII) activity, which is crucial for gene expression. HEXIM1 achieves this by controlling the location and activity of positive transcription factor β (P-TEFb), a key regulator of RNAPII .
One of the most significant roles of HEXIM1 is its ability to inhibit metastasis in cancer cells. Studies have shown that HEXIM1 expression is decreased in human metastatic breast cancers compared to primary breast tumors . Re-expression of HEXIM1 in breast cancer models has been shown to inhibit metastasis to the lungs by downregulating HIF-1α protein, which in turn inhibits vascular endothelial growth factor (VEGF)-regulated angiogenesis . This makes HEXIM1 a potential therapeutic target for cancer treatment.
HEXIM1 also plays a crucial role in erythropoiesis, the process of red blood cell formation. It regulates erythroid proliferation and fetal globin expression in a positive transcription factor β-dependent manner . HEXIM1 enforces RNAPII pausing at cell cycle checkpoint genes and increases RNAPII occupancy at genes that promote cell cycle progression. This regulation is essential for the proper development and function of erythroid cells .
Given its role in inhibiting metastasis and regulating erythropoiesis, HEXIM1 has significant therapeutic potential. In cancer therapy, targeting HEXIM1 could help inhibit tumor growth and metastasis. In hematological disorders, manipulating HEXIM1 activity could enhance erythropoiesis and improve outcomes for patients with anemia or other red blood cell disorders .
